Australian biotech firm Telix Pharmaceuticals is buying Germany’s ITM Isotope Technologies in Munich for roughly $1.65 billion. The massive deal is a major power move for Telix, giving it a much stronger foothold in the rapidly growing radiopharmaceutical cancer treatment market.
As part of closing the deal, ITM shareholders will receive $1.25 billion in Telix shares, each worth $11.84. In addition, the deal includes a provision for bonus payments totalling $700 million upon meeting certain milestones. These milestones will be achieved if ITM’s newly developed cancer drug ITM-11 passes through the regulatory requirements and achieves a sales target. The drug ITM-11 targets gut and pancreatic tumours.
This buyout is highly strategic for Telix. ITM isn’t just a research company; they already run a profitable, large-scale medical isotope production business. Buying them out means Telix secures its own supply chain for making therapies, while bringing in a steady stream of revenue right away. Telix investors will own 76.3% of the combined business, and ITM’s team will hold the remaining 23.7%.
You Might Also Like: Meta Launches New ‘Meta One’ AI Subscription Tiers
Future expectations point to a combined company which is expected to generate more than $1.3 billion in revenue by 2026. Management believes profits will turn positive by 2027, driven by cost savings from overlapping operations and increased drug production. If ITM-11 receives regulatory approval, the profits may rise even quicker. The acquisition seems almost sure to be completed, since both boards have approved it, and 90% of ITM shareholders have supported it. Nonetheless, the market response has been hesitant, as Telix’s stock fell 4.8% to A$16.82.
